interferon
ifn
first
line
defens
viral
infect
herein
describ
use
adenoviru
vector
mous
ifn
alpha
gene
prophylact
treatment
countermeasur
sarscovinfect
balbc
mous
model
complet
surviv
protect
observ
mice
given
singl
dose
administ
intranas
day
prior
lethal
sarscov
challeng
p
bodi
weight
treat
mice
unaffect
challeng
addit
low
dose
protect
lung
dose
depend
manner
measur
reduct
gross
patholog
intranas
treatment
rang
pfu
significantli
protect
mice
lethal
sarscov
infect
dose
depend
manner
h
post
infect
p
data
suggest
new
class
antivir
agent
develop
treatment
sarscov
infect
sever
acut
respiratori
syndrom
sar
emerg
infecti
diseas
caus
novel
human
coronaviru
sarscov
result
sever
pulmonari
patholog
failur
ksiazek
et
al
peiri
et
al
katz
et
al
due
high
morbid
mortal
sar
consid
import
global
respiratori
diseas
risk
epidem
even
popul
new
infect
therefor
develop
new
antisarscov
agent
experiment
clinic
research
warrant
control
futur
outbreak
sinc
sar
pose
signific
threat
public
health
repres
challeng
antivir
drug
develop
administr
groneberg
et
al
groneberg
et
al
numer
type
agent
test
sarscov
vitro
vivo
notabl
antibodi
sarscov
spike
protein
shown
block
entri
sui
et
al
small
peptid
deriv
heptad
repeat
hr
region
sarscov
protein
shown
inhibit
sarscov
infect
interfer
sarscov
fusion
target
cell
bosch
et
al
ho
et
al
addit
main
proteas
sarscov
essenti
replic
cycl
sarscov
key
target
develop
antisar
drug
yang
et
al
antisens
rna
rna
interfer
sirna
technolog
shown
potenti
treat
sever
diseas
includ
sarscov
infect
ahlquist
gibson
johnsonsaliba
jan
leonard
schaffer
use
sirna
inhibit
sarscov
infect
rhesu
macaqu
demonstr
sirna
effect
prophylact
therapeut
vivo
chang
et
al
effect
like
due
viru
specif
inhibit
due
induct
interferon
siconab
use
studi
contain
neither
motif
suspect
immunostimulatori
element
use
transfect
reagent
judg
et
al
addit
also
signific
concern
regard
toxic
issu
use
sirna
frantz
previous
describ
inhibitori
role
compound
approv
therapeut
use
human
evalu
promis
vitro
inhibitor
sarscov
mous
model
shown
activ
ifn
pathway
result
signific
protect
barnard
et
al
ifn
alpha
bd
ifn
induc
ampligen
poli
poli
shown
potent
inhibit
viru
titer
lung
infect
mice
barnard
et
al
furthermor
ifnalfacon
inhibit
sarscov
infect
human
bronchial
epitheli
cell
kumaki
et
al
recent
also
shown
intranas
treatment
interferon
induc
polyriboinosinicpolyribocytidyl
acid
stabil
polyllysin
carboxymethyl
cellulos
poli
iclc
hiltonol
effect
protect
mice
lethal
infect
mouseadapt
sarscov
reduc
viral
lung
titer
kumaki
et
al
recombin
interferon
extens
research
therapeut
properti
effect
safe
recombin
human
protein
broad
clinic
appeal
brassard
et
al
howev
recombin
great
therapeut
valu
use
hinder
short
halflif
termin
halflif
interferon
alfacon
follow
subcutan
dose
h
golden
syrian
hamster
h
rhesu
monkey
blatt
et
al
due
rapid
decay
multipl
inject
requir
address
rapid
degrad
pegyl
introduc
halfliv
order
day
instead
hour
thu
reduc
number
inject
per
week
bell
et
al
circumv
fast
vivo
decay
develop
gene
deliveri
platform
deliv
mous
gene
subtyp
constitut
drive
product
situ
ifn
speci
specif
mous
ifn
gene
requir
denot
normal
deliv
intranas
studi
suggest
intranas
administr
prevent
host
immun
system
recogn
vector
therebi
bypass
preexist
immun
present
clinic
scenario
croyl
et
al
addit
intranas
administr
allow
needlefre
dose
reduc
need
medic
personnel
therebi
facilit
mass
distribut
event
epidem
weaver
barri
shown
defens
research
develop
canada
drdc
suffield
provid
preand
postexposur
protect
western
equin
enceph
viru
weev
wu
et
al
thu
find
illustr
function
system
murin
model
suggest
adenovirusmedi
express
could
altern
approach
prevent
treatment
viral
infect
report
evalu
use
prophylact
treatment
therapeut
countermeasur
treat
lethal
sar
infect
balbc
mice
caus
mouseadapt
sarscov
vero
cell
obtain
american
type
cultur
collect
atcc
manassa
va
routin
grown
minim
essenti
medium
mem
supplement
heatinactiv
fetal
bovin
serum
fb
thermo
fisher
scientif
co
logan
ut
vitro
antivir
assay
serum
reduc
fb
gentamicin
ad
medium
final
concentr
gml
cov
strain
urbani
obtain
center
diseas
control
prevent
cdc
atlanta
ga
usa
strain
propag
titrat
vero
cell
mouseadapt
sarscov
strain
previous
describ
day
et
al
viru
use
experi
passag
time
balbc
mice
verifi
sarscov
elisa
pcr
viru
mutat
one
affect
two
read
frame
result
chang
amino
acid
residu
compar
wild
type
urbani
four
mutat
occur
spike
protein
region
day
et
al
put
ga
mutat
observ
base
pair
replic
found
rna
infect
mous
lung
mutat
compar
lethal
strain
robert
et
al
reveal
interest
similar
differ
mutat
spectra
associ
mous
adapt
young
balbc
mice
structur
gene
mutat
spike
region
conserv
strain
mmutat
similar
locat
lethal
strain
replicas
gene
mutat
locat
near
mutat
found
strain
lethal
strain
mutat
mous
model
infect
anim
die
day
mortal
achiev
day
day
et
al
infect
mous
gross
lung
patholog
character
sever
inflam
lung
surfac
sever
discolor
lung
dark
plumcolor
weight
loss
excess
rel
viru
exposur
occasion
surviv
anim
may
lose
weight
surviv
mice
regain
initi
weight
day
live
least
day
viru
titer
lung
exceed
ml
titer
peak
day
mice
surviv
viru
lung
titer
persist
least
day
day
et
al
dose
pfu
use
infect
mice
experi
involv
infecti
virus
conduct
approv
select
agentapprov
biosafeti
level
laboratori
use
appropri
person
protect
equip
construct
describ
previous
wu
et
al
briefli
mous
interferon
alpha
gene
clone
replic
defici
vector
delet
gene
amplifi
cell
purifi
cesium
chlorid
gradient
centrifug
stock
solut
alpha
defyru
inc
toronto
ontario
canada
provid
pfuml
store
c
ifn
induc
polyriboinosinicpolyribocytidyl
acid
stabil
polyllysin
carboxymethyl
cellulos
poli
iclc
obtain
andr
salazar
oncovir
inc
wa
dc
poli
iclc
dilut
physiolog
steril
salin
pss
vivo
experi
use
specif
pathogenfre
femal
g
balbc
mice
obtain
charl
river
laboratori
wilmington
studi
maintain
wayn
lab
blox
fed
standard
mous
chow
tap
water
ad
libitum
balbc
mice
quarantin
h
prior
use
anim
studi
carri
certifi
biosafeti
level
anim
facil
personnel
enter
facil
wore
power
airpurifi
respir
hepa
airmat
saint
paul
mn
tyvek
bodi
protect
suit
anim
studi
approv
utah
state
univers
anim
care
committe
gener
experiment
design
describ
balbc
mice
anesthet
ml
intraperiton
inject
mgkg
ketamin
challeng
sarscov
intranas
volum
ml
group
mice
administ
dose
time
administr
vari
describ
section
intranas
challeng
pfu
mouseadapt
sarscov
poli
iclc
administ
h
viru
exposur
h
exposur
viru
serv
posit
control
control
viral
infect
fifteen
mice
treat
vehicl
placebo
pss
pb
empti
vector
express
variou
time
prior
viru
exposur
depend
experi
mice
group
repres
placebo
control
sarscovinfect
mockinfect
mice
weigh
everi
day
clinic
sign
diseas
also
observ
record
daili
anim
death
record
day
post
viru
exposur
anim
lost
greater
initi
bodi
weight
human
euthan
co
asphyxi
day
euthan
design
day
death
due
infect
dose
rang
find
experi
carri
determin
effect
administr
anim
bodi
weight
overt
measur
toxicolog
three
mice
use
per
treatment
group
toxic
evalu
term
weight
chang
advers
event
mice
weigh
everi
day
h
prior
viru
infect
day
post
exposur
advers
event
observ
made
includ
ruffl
fur
lethargi
paralysi
incontin
repetit
circular
motion
aggress
overt
toxic
advers
event
detect
five
mice
low
dose
group
sacrif
day
lung
sampl
lobe
weigh
place
petri
dish
lung
score
base
surfac
appear
assign
score
rang
indic
normal
appear
denot
entir
surfac
area
lung
exhibit
discolor
lung
score
score
repres
observ
gross
patholog
lung
surfac
thu
surfac
lung
exhibit
plumcolor
discolor
andor
hemorrhag
sidwel
et
al
signific
differ
analyz
kruskalw
test
follow
dunn
posttest
evalu
signific
pairwis
comparison
mice
weigh
group
prior
treatment
everi
day
thereaft
determin
averag
weight
chang
anim
treatment
group
weight
express
group
averag
day
evalu
statist
signific
twoway
analysi
varianc
sinc
statist
signific
achiev
signific
differ
two
treatment
group
analyz
bonferroni
pairwis
comparison
test
surviv
analys
first
conduct
use
kaplanmei
method
logrank
test
signific
differ
among
treatment
group
observ
pairwis
comparison
survivor
curv
pss
vs
treatment
analyz
gehanbreslowwilcoxon
test
rel
signific
adjust
bonferronicorrect
signific
threshold
number
treatment
comparison
done
mean
day
death
death
caus
diseas
calcul
analyz
kruskalw
test
follow
dunn
posttest
evalu
signific
pairwis
comparison
live
number
per
total
mice
group
differ
evalu
conting
tabl
analysi
preliminari
studi
determin
toxic
record
weight
chang
observ
advers
advent
uninfect
mice
randomli
assign
treatment
group
mice
administ
intranas
pfu
h
prior
challeng
mouseadapt
viru
mice
gain
weight
rate
indistinguish
mice
receiv
pss
data
shown
mice
treat
poli
iclc
group
lose
notic
amount
weight
regain
lost
bodi
weight
day
end
experi
gain
equal
group
advers
event
observ
toxic
control
mice
use
experi
data
shown
protect
balbc
mice
lethal
dose
sarscovinfect
pfu
placebo
pss
pb
intranas
administ
lnare
h
prior
challeng
pfu
mouseadapt
sarscov
ifn
induc
poli
iclc
mgkg
given
intranas
mice
h
h
viru
exposur
surviv
rate
group
monitor
daili
determin
day
infect
treatment
either
poli
iclc
intranas
rout
effect
protect
mice
lethal
infect
mouseadapt
sarscov
p
fig
mice
receiv
treatment
also
significantli
protect
infect
relat
weight
loss
data
shown
p
day
either
dose
vs
empti
vector
pss
sever
mice
placebo
group
also
surviv
challeng
probabl
due
natur
suscept
variat
speci
mous
dose
pfu
vehicl
placebo
administ
intranas
day
prior
challeng
pfu
mouseadapt
sarscov
complet
surviv
record
mice
treat
singl
dose
time
point
prior
challeng
p
fig
mice
receiv
prophylact
also
significantli
protect
weight
loss
due
infect
p
fig
one
mous
surviv
placebotr
group
regain
weight
previous
describ
day
et
al
sarscovinfect
femal
balbc
mice
administ
pfu
vehicl
placebo
intranas
h
prior
challeng
mouseadapt
viru
mice
weigh
everi
day
day
weight
loss
clinic
sign
observ
mice
receiv
prophylac
tic
dose
pfu
significantli
protect
mortal
p
fig
infect
mice
receiv
pfu
also
protect
seriou
weight
loss
suffer
mice
receiv
placebo
pss
fig
surviv
mice
receiv
pfu
poli
iclc
went
recov
weight
end
experi
fig
mice
treat
pfu
trend
toward
less
weight
loss
rel
mice
treatment
group
placebotr
mice
contrast
lower
dose
significantli
protect
death
amelior
weight
loss
infect
mice
critic
day
infect
day
fig
efficaci
describ
also
support
gross
patholog
score
lung
low
dose
infect
mice
record
dose
day
fig
effect
lung
score
femal
balbc
mice
infect
lethal
dose
mouseadapt
sarscov
day
mous
lung
lobe
remov
weigh
place
plastic
dish
assign
score
rang
normal
appear
lung
maxim
plum
color
lung
scatter
plot
report
individu
valu
mean
sd
indic
horizont
bar
signific
lung
score
differ
treatment
group
determin
use
kruskalw
test
follow
dunn
posttest
evalu
signific
pairwis
comparison
signific
lung
weight
differ
compar
placebotr
mice
evalu
analysi
varianc
individu
treatment
valu
compar
pss
control
use
newmankeul
pairwis
comparison
test
pss
pfu
pfu
pfu
pfu
h
pfu
h
pfu
h
pfu
h
pfu
h
poli
iclc
mgkg
h
p
p
compound
vs
pss
viru
exposur
fig
day
pfu
afford
signific
protect
surfac
hemorrhag
observ
infect
vehicl
placebotr
mice
p
fig
compar
placebotr
mice
mice
receiv
pfu
also
display
significantli
less
surfac
patholog
p
well
mice
receiv
poli
iclc
p
effect
viru
lung
titer
phenomenon
report
other
use
interferon
treat
sar
infect
anim
smit
et
al
efficaci
treatment
sarscov
infect
evalu
pfu
intranas
h
postchalleng
pfu
dose
result
surviv
administ
h
postchalleng
time
clinic
sign
weight
loss
sar
manifest
untreat
balbc
mice
p
fig
dose
pfu
dose
protect
given
h
sarscov
infect
fig
subsequ
therapeut
experi
even
higher
dose
pfu
administ
intranas
h
postchalleng
empti
vector
neg
control
anim
treat
pfu
h
post
infect
surviv
significantli
protect
mice
weight
loss
day
post
viru
exposur
p
data
shown
addit
anim
treat
pfu
show
mark
increas
surviv
treat
late
h
post
infect
fig
although
observ
trend
toward
protect
weight
loss
statist
signific
protect
observ
later
time
point
effort
recapitul
human
diseas
employ
sarscov
infect
balbc
mous
model
surrog
sarscov
infect
human
respiratori
tract
site
viru
inocul
day
et
al
previou
data
reveal
peak
viral
load
ml
approxim
day
post
sarscov
infect
kumaki
et
al
extrapol
rodent
data
macaqu
model
macaca
fasciculari
dose
protect
sarscovinfect
anim
given
prophylact
haagman
et
al
preliminari
human
clinic
studi
loutfi
et
al
test
ifnalfacon
combin
corticosteroid
assess
potenti
clinic
benefit
safeti
sar
patient
data
demonstr
signific
benefit
patient
receiv
ifn
alfacon
suggest
repeat
dose
ifn
alon
corticosteroid
may
function
antivir
therapeut
treatment
sar
patient
loutfi
et
al
current
studi
mice
administ
prophylact
two
week
prior
viral
challeng
surviv
viru
infect
addit
therapeut
protect
anim
administ
h
challeng
dose
depend
manner
believ
constitut
express
provid
stimul
innat
immun
respons
effect
suppress
sarscov
challeng
result
signific
surviv
benefit
especi
administ
prophylact
normal
host
innat
immun
respons
viru
insult
includ
product
ifn
type
initi
limit
viral
replic
virusinfect
cell
usual
caus
activ
sever
transcript
factor
ifn
regulatori
factor
play
central
role
downstream
gene
activ
lin
et
al
ifn
synthes
secret
cell
bind
cell
surfac
receptor
induc
transcript
result
antivir
state
target
cell
howev
product
ifn
type
sarscovinfect
cell
limit
chen
subbarao
spiegel
et
al
neither
endogen
ifn
transcript
ifn
promot
activ
detect
spiegel
et
al
lack
ifn
activ
attribut
protein
perhap
virion
nonstructur
protein
sarscov
antagon
ifn
block
transcript
factor
necessari
express
ifn
kopeckybromberg
et
al
protein
sarscov
report
antagon
product
immunomodulatori
effect
endogen
ifn
nucleocapsid
protein
n
sarscov
shown
inhibit
ifnbeta
induc
poli
ic
lu
et
al
studi
author
found
n
protein
inhibit
product
due
overexpress
downstream
signal
molecul
tolllik
receptor
rigilik
receptor
rlr
depend
pathway
like
sarscov
n
protein
target
initi
step
probabl
cellular
prr
pattern
recognit
receptor
rnasrecognit
step
innat
immun
pathway
suppress
ifn
express
respons
lu
et
al
addit
nonstructur
protein
sarscov
also
found
modul
interferon
induct
protein
shown
suppress
type
interferon
product
promot
host
mrna
degrad
inhibit
host
translat
infect
cell
kamitani
et
al
yet
despit
inhibitori
molecul
viru
remain
suscept
exogen
ifn
chen
subbarao
interest
neither
wild
type
viru
gene
product
modul
ifn
pathway
ifn
express
alter
mous
adapt
urbani
strain
sarscov
use
current
studi
day
et
al
previous
shown
effect
sarscov
infect
vitro
studi
report
potent
inhibit
sarscov
infect
replic
exogen
less
effici
chen
et
al
cinatl
et
al
dahl
et
al
tan
et
al
zheng
et
al
term
ifn
induc
recent
report
intranas
treatment
poli
iclc
protect
mice
lethal
mouseadapt
sarscov
infect
reduc
viral
load
lung
kumaki
et
al
poli
iclc
effect
therapi
initi
h
infect
within
h
viru
inocul
current
studi
similar
efficaci
achiev
protect
mice
death
interferon
induc
also
vector
constitut
express
interferon
also
without
substanti
reduc
viral
lung
titer
similar
result
obtaineod
other
use
interferon
treat
sar
infect
et
al
smit
et
al
regard
worth
note
mice
infect
nonmous
adapt
strain
sarscov
alway
support
vigor
replic
viru
lung
viru
lung
titer
peak
h
post
viru
exposur
continu
remain
compar
level
day
infect
day
infect
viru
replic
ceas
dramat
slow
viru
clear
within
two
day
thereaft
subbarao
et
al
rockx
et
al
pathogenesi
detect
could
current
studi
later
induct
interferon
pathway
upregul
suffici
control
damag
host
yet
allow
certain
amount
viru
replic
exampl
despit
viru
sensit
sarscov
still
replic
rapidli
lung
mice
previous
mention
previous
shown
nonlymphat
cell
infect
sarscov
neither
dimer
stabl
nuclear
accumul
ifnregulatori
factor
occur
spiegel
et
al
protein
key
role
transactiv
promot
addit
initi
product
interferon
normal
trigger
express
relat
factor
sarscov
infect
honda
et
al
kuri
et
al
latter
studi
kuri
et
al
recent
show
result
suggest
interferon
produc
plasmacytoid
dendrit
cell
could
enabl
cell
launch
host
respons
sarscov
may
activ
subdetect
level
still
function
promot
interferon
respons
sarscov
infect
activ
thu
activ
might
necessari
reduc
viru
lung
titer
earli
infect
later
induct
interferon
pathway
might
suffici
control
damag
effect
viru
replic
lung
trigger
virusinduc
cytokin
storm
ard
rockx
et
al
smit
et
al
advantag
method
interferon
deliveri
paraga
et
al
report
ifnalfacon
antisarscov
activ
prior
infect
cellbas
model
vitro
case
ifnalfacon
like
induc
antivir
state
target
cell
produc
cellular
environ
suitabl
viral
replic
howev
ifnalfacon
protect
cell
ad
post
infect
wherea
afford
compet
surviv
even
ad
h
viru
infect
gave
partial
protect
high
dose
h
post
viru
exposur
illustr
benefit
constitut
express
interferon
use
vector
studi
need
conduct
direct
comparison
ifn
protein
elucid
addit
like
lower
dose
given
period
week
case
concept
could
counter
rapid
degrad
toxic
associ
bolu
dose
interferon
thu
benefit
approach
convent
therapi
recombin
human
ifn
interferon
induc
includ
singl
intranas
dose
vs
repeat
inject
dose
b
extend
therapeut
window
benefit
extrapol
clinic
set
could
util
largescal
sar
epidem
postexposur
prophylact
treatment
facilit
quick
easi
dissemin
atrisk
popul
medic
chain
worker
short
approach
retain
proven
clinic
benefit
manag
sarscov
infect
overcom
short
halflif
limit
exogen
ifn
ifn
induc
broadli
given
efficaci
profil
shown
wu
et
al
signific
potenti
broad
spectrum
hostdirect
antivir
although
ifn
could
theoret
ideal
antivir
agent
therapeut
valu
limit
sinc
effect
rel
short
period
high
dose
seriou
toxic
effect
host
therefor
attempt
use
exogen
ifn
treatment
human
viral
diseas
also
met
limit
success
address
issu
defyru
develop
technolog
util
gene
deliveri
platform
deliv
human
ifnalpha
gene
drive
ifnalpha
product
situ
intranas
administr
prevent
recognit
host
immun
system
addit
shelfstabl
powder
formul
administ
allow
easi
storag
administr
event
need
mass
distribut
